Accurately diagnosing T-cell lymphoma often takes time. Given that cutaneous T-cell lymphoma shares symptoms with many other benign conditions, it takes an average of 6 years from disease onset to ...

The following is a summary of “Hematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study,” published in the March 2025 issue of Journal of the ...

The Johns Hopkins T-cell and Cutaneous Lymphoma Program provides expertise in all forms of systemic peripheral T-cell lymphomas and cutaneous T-cell lymphomas, including mycosis fungoides and others.

extranodal T-cell lymphoma, cutaneous T-cell lymphomas (Sézary syndrome and Mycosis fungoides), anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma.

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma,” published in the February 2025 issue of ...

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

We have 3 FDA-approved autologous CAR T-cell therapies for relapsed and refractory large B-cell lymphoma that can be treated. Patients can get those treatments as a third or later line with 3 ...

Panelists discuss how ciltacabtagene autoleucel (cilta-cel) demonstrates superior outcomes compared to real-world physician’s ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...